Synlett 2021; 32(18): 1874-1878
DOI: 10.1055/a-1579-1692
letter

An Efficient Protocol for the Synthesis of Pyrazolo[1,5-c]quinazolines by a Staudinger–Aza-Wittig–Dehydroaromatization Sequence

Mingxian Xu
,
An Chen
,
Zhilin Ren
,
Jiying Qiu
,
Mingming Zu
,
Yi Zhang
,
Jiayi Wang
,
Ping He
This work was supported by the Key Project of Hubei Educational Committee (No. D20182602), the Doctoral Startup Foundation of Hubei University of Arts and Science, and the Student Innovation Training Program (No. X202110519136)


Abstract

The one-pot synthesis of azide-substituted dihydropyrazoles in isopropanol was performed by using chalcones, hydrazine hydrate, and an acyl chloride at 0 ℃. Subsequent Staudinger–aza-Wittig–dehydroaromatization reactions of the products with methyl(diphenyl)phosphine were also investigated for further application in the construction of pyrazolo[1,5-c]quinazolines.

Supporting Information



Publication History

Received: 14 July 2021

Accepted after revision: 05 August 2021

Accepted Manuscript online:
05 August 2021

Article published online:
18 August 2021

© 2021. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References and Notes

  • 1 Garg M, Chauhan M, Singh PK, Alex JM, Kumar R. Eur. J. Med. Chem. 2015; 97: 444
    • 2a Traquandi G, Ciomei M, Ballinari D, Casale E, Colombo N, Croci V, Fiorentini F, Isacchi A, Longo A, Mercurio C, Panzeri A, Pastori W, Pevarello P, Volpi D, Roussel P, Vulpetti A, Brasca MG. J. Med. Chem. 2010; 53: 2171
    • 2b Brasca MG, Amboldi N, Ballinari D, Cameron A, Casale E, Cervi G, Colombo M, Colotta F, Croci V, D’Alessio R, Fiorentini F, Isacchi A, Mercurio C, Moretti W, Panzeri A, Pastori W, Pevarello P, Quartieri F, Roletto F, Traquandi G, Vianello P, Vulpetti A, Ciomei M. J. Med. Chem. 2009; 52: 5152
    • 2c Beria I, Ballinari D, Bertrand JA, Borghi D, Bossi RT, Brasca MG, Cappella P, Caruso M, Ceccarelli W, Ciavolella A, Cristiani C, Croci V, De Ponti A, Fachin G, Ferguson RD, Lansen J, Moll JK, Pesenti E, Posteri H, Perego R, Rocchetti M, Storici P, Volpi D, Valsasina B. J. Med. Chem. 2010; 53: 3532
    • 2d Colquhoun A, Lawrance GM, Shamovsky IL, Riopelle RJ, Ross GM. J. Pharmacol. Exp. Ther. 2004; 310: 505
    • 2e Orvieto F, Branca D, Giomini C, Jones P, Koch U, Ontoria JM, Palumbi MC, Rowley M, Toniatti C, Muraglia E. Bioorg. Med. Chem. Lett. 2009; 19: 4196
    • 2f Nagarajan S, Skoufias DA, Kozielski F, Pae AN. J. Med. Chem. 2012; 55: 2561
    • 2g Kumar D, Kaur G, Negi A, Kumar S, Singh S, Kumar R. Bioorg. Chem. 2014; 57: 57
  • 4 Beaulieu F, Ouellet C, Ruediger EH, Belema M, Qiu Y, Yang X, Banville J, Burke JR, Gregor KR, MacMaster JF, Martel A, McIntyre KW, Pattoli MA, Zusi FC, Vyas D. Bioorg. Med. Chem. Lett. 2007; 17: 1233
  • 5 Varano F, Catarzi D, Colotta V, Lenzi O, Filacchioni G, Galli A, Costagli C. Bioorg. Med. Chem. 2008; 16: 2617
  • 6 Varano F, Catarzi D, Colotta V, Filacchioni G, Galli A, Costagli C, Carlà V. J. Med. Chem. 2002; 45: 1035
  • 7 Colotta V, Catarzi D, Varano F, Filacchioni G, Cecchi L, Galli A, Costagli C. J. Med. Chem. 1996; 39: 2915
  • 8 Asproni B, Murineddu G, Pau A, Pinna GA, Langgård M, Christoffersen CT, Nielsen J, Kehler J. Bioorg. Med. Chem. 2011; 19: 642
  • 9 Sawant DM, Sharma S, Pathare RS, Joshi G, Kalra S, Sukanya S, Maurya AK, Metre RK, Agnihotri VK, Khan S, Kumar R, Pardasani RT. Chem. Commun. 2018; 54: 11530
  • 10 Catarzi D, Colotta V, Varano F, Poli D, Squarcialupi L, Filacchioni G, Varani K, Vincenzi F, Borea PA, Dal Ben D, Lambertucci C, Cristalli G. Bioorg. Med. Chem. 2013; 21: 283
    • 16a Mathuber M, Schueffl H, Dömötör O, Karnthaler C, Enyedy ÉA, Heffeter P, Keppler BK, Kowol CR. Inorg. Chem. 2020; 59: 17794
    • 16b Parveen S, Alnoman RB, Hagar M, Ahmed HA, Knight JG. ChemistrySelect 2020; 5: 13163
    • 16c Jang J, To C, De Clercq DJ. H, Park E, Ponthier CM, Shin BH, Mushajiang M, Nowak RP, Fischer ES, Eck MJ, Jänne PA, Gray NS. Angew. Chem. Int. Ed. 2020; 59: 14481
    • 16d Lin C, Ren Z, Yang X, Yang R, Chen Y, Liu Z, Dai Z, Zhang Y, He Y, Zhang C, Wang X, Cao W, Ji T. Cancer Lett. 2020; 472: 81
    • 16e Fernandes Neto JM, Nadal E, Bosdriesz E, Ooft SN, Farre L, McLean C, Klarenbeek S, Jurgens A, Hagen H, Wang L, Felip E, Martinez-Marti A, Vidal A, Voest E, Wessels LF. A, van Tellingen O, Villanueva A, Bernards R. Nat. Commun. 2020; 11: 3157
  • 22 For proposed intermediates condensed from hydrazine and chalcones, see: Dhakshinamoorthy A, Alvaro M, Garcia H. Adv. Synth. Catal. 2009; 351: 2271
  • 23 1-Acyl-5-(2-azidophenyl)-4,5-dihydropyrazoles 4ap: General Procedure Hydrazine hydrate (2; 3 mmol) was added to a stirred solution of the appropriate azidochalcone 1 (3 mmol) in i-PrOH (10 mL) at 0 °C, and the mixture was vigorously stirred until the reaction was complete (TLC). Acyl chloride 3 (3.3 mmol) was then added dropwise and the mixture was allowed to warm to r.t. The precipitated solid was collected, washed with EtOH, and crystallized from CH2Cl2–PE. 5-(2-Azidophenyl)-1-(4-chlorobenzoyl)-3-phenyl-4,5-dihydro-1H-pyrazole (4a) White crystals; yield: 1095 mg (91%); mp 164–165 ℃. IR (KBr): 3387, 2927, 2858, 2129, 1639, 1597, 1489, 1423, 1284, 1087, 748 cm–1. 1H NMR (400 MHz, CDCl3): δ = 8.03 (d, J = 8.4 Hz, 2 H, Ar-H), 7.70–7.68 (m, 2 H, Ar-H), 7.44–7.39 (m, 5 H, Ar-H), 7.34–7.30 (m, 1 H, Ar-H), 7.22–7.17 (m, 2 H, Ar-H), 7.11–7.07 (m, 1 H, Ar-H), 5.98 (q, J = 5.6 Hz, 1 H, Ar-CH), 3.79 (dd, J1 = 11.6, J2 = 17.6 Hz, 1 H, CH), 3.08 (dd, J1 = 5.6, J2 = 17.6 Hz, 1 H, CH). 13C NMR (100 MHz, CDCl3): δ = 165.1, 155.4, 137.2, 136.7, 132.5, 132.0, 131.7, 131.1, 130.5, 128.9, 128.7, 127.9, 126.7, 126.2, 125.2, 118.6, 57.2, 40.8. LC-MS: m/z = 401. Anal. Calcd for C22H16ClN5O: C, 65.76; H, 4.01; N, 17.43. Found: C, 65.79; H, 4.05; N, 17.40.
  • 25 Pyrazolo[1,5-c]quinazolines 8; General Procedure A solution of methyl(diphenyl)phosphine (0.20 g, 1 mmol) in toluene (5 mL) was added dropwise to a stirred solution of the appropriate 1-acyl-5-(2-azidophenyl)-4,5-dihydropyrazole 4 (1 mmol) in toluene (5 mL) at r.t. The mixture was stirred at r.t. for 2 h and then refluxed for 1–6 h until the reaction was complete (TLC). The solvent was then removed under reduced pressure, and the residue was crystallized from CH2Cl2–PE. 2-(4-Chlorophenyl)-5-phenylpyrazolo[1,5-c]quinazoline (8a) White crystals; yield: 305 mg (86%); mp 171–172 ℃. IR (KBr): 3431, 1618, 1610, 1490, 1436, 1402, 1367, 1282, 1180, 1091, 943, 825, 746, 682, 597, 557 cm–1. 1H NMR (400 MHz, CDCl3): δ = 8.56–8.54 (m, 2 H, Ar-H), 8.10–7.99 (m, 4 H, Ar-H), 7.70–7.41 (m, 7 H, Ar-H), 7.36 (s, 1 H, Ar-H). 13C NMR (100 MHz, CDCl3): δ = 154.8, 146.3, 141.9, 139.9, 137.1, 132.3, 132.1, 131.2, 129.9, 129.2, 128.8, 128.7, 128.4, 127.8, 126.8, 123.0, 119.5, 95.3. LC-MS: m/z = 355. Anal. Calcd for C22H14ClN3: C, 74.26; H, 3.97; N, 11.81. Found: C, 74.29; H, 3.91; N, 11.88.